TLDR: EVERSANA, in collaboration with Google, has launched a groundbreaking end-to-end AI agency product designed to fundamentally reshape pharmaceutical marketing. This new system leverages interlocking AI agents and sub-agents to streamline brand planning, competitive analysis, omnichannel execution, and content creation, promising faster, more cost-effective, and compliant commercialization strategies. The model emphasizes an 80% AI, 20% human collaboration, ensuring accuracy and regulatory adherence by operating within secure corporate data environments.
Pharmaceutical marketing is an inherently complex and multifaceted undertaking, encompassing everything from initial brand planning and competitive analysis to engaging both prescribers and patients, navigating stringent regulatory landscapes, and generating vast amounts of bespoke content for omnichannel campaigns. While many pharma marketing agencies have begun to integrate AI tools, their application often remains piecemeal, addressing individual challenges rather than transforming the entire process. However, a new paradigm has emerged with EVERSANA’s recent unveiling of its end-to-end AI agency product, developed in partnership with Google.
At a recent event held on Google’s New York City campus, EVERSANA CEO Jim Lang highlighted the immense financial scale of pharmaceutical commercialization, stating, “Most people don’t realise that of the $1.1 trillion we spend on medicines around the globe, about $150 billion is spent on commercialisation.” This figure, he noted, surpasses the expenditures on manufacturing or clinical trials, underscoring the critical need for a more efficient approach. The ‘better way’ presented by EVERSANA and Google is a sophisticated system of interconnected AI agents and sub-agents, each tasked with specific components of the marketing workflow. Unlike traditional human-centric processes, this AI-driven system integrates critical steps, such as medical, legal, and regulatory (MLR) claim management, from the very outset of the marketing journey, as explained by Faruk Capan, EVERSANA’s chief innovation officer.
The system is structured around three primary master agents: business strategy, omnichannel, and content creation, each supported by a network of specialized sub-agents. This architecture enables a small team of human experts to execute complex marketing tasks with unprecedented speed and efficiency. During the demonstration, EVERSANA’s Shane Mayer showcased the system’s ability to rapidly generate a competitive analysis and business strategy for a fictional cell therapy company. The system also demonstrated its agility by quickly adapting the strategy to focus on unseating a single market leader, rather than a broader competitive field. Throughout these processes, integrated ‘oversight agents’ continuously monitor output for accuracy and compliance.
Perhaps the most striking aspect of the demonstration was the AI’s capability in content creation. Kathleen Ferry of EVERSANA presented an AI-generated product advertisement that, she claimed, took only one day to concept and another day to produce, showcasing a significant leap in creative output efficiency.
Addressing concerns about accuracy and potential AI ‘hallucinations,’ EVERSANA and Google emphasized two key safeguards: high-quality input data and highly specialized AI agents. Abid Rahman clarified that these are not general large language models but rather ‘very distinct and discrete’ agents ‘trained to do very unique things,’ with specific knowledge boundaries. Ryan Terry, managing director for healthcare and life sciences at Google Cloud, further elaborated on data security, stating, “We made it completely accessible inside of your own corporate data.” He assured that partner data remains private, is not used for training Google’s models, research, or advertising, thereby significantly reducing the margin of error in campaign development.
The operational model of this new agency product is designed around an 80% AI, 20% human collaboration. This blend allows for a much smaller human team compared to traditional full-service agencies, with clients interacting with ‘a handful of people’ who are adept at leveraging the system’s capabilities. Notably, the service will be billed at a flat rate, moving away from the conventional hourly billing model. Faruk Capan highlighted that this approach demands a different mindset and workflow from the human team, as ‘everything’s going to be so fast and at the same time, provide it to you on the go.’
The depth of the partnership with Google was a central theme of the launch. The event’s location on Google’s campus and the participation of Google executives, including Terry and Dr. Peter Clardy (lead for the Google for Health Clinical Enterprise Team), underscored a collaboration extending beyond mere Google Cloud tool usage. Terry revealed that EVERSANA receives ‘full access to an understanding of our R&D, early access to our technology, access to our physicians, our researchers, the cutting-edge things we do behind curtains.’ Dr. Clardy also reiterated Google’s long-standing commitment to data privacy and security in healthcare, emphasizing that AI is brought ‘to the data where it lives,’ without transferring private partner data to Google.
Also Read:
- Lumanity Unveils Expert-Directed AI Platform to Enhance Healthcare Value Demonstration
- Atlas and Google Cloud Collaborate to Unveil AI-Powered Game Development Platform
While the long-term implications and performance of such a system remain to be fully observed – particularly regarding its hallucination-proof nature, the efficacy of regulatory oversight agents, and its impact on the pharma marketing job market – EVERSANA asserts that this is not a mere concept. Parts of the system are already in use with clients, and the comprehensive end-to-end solution is ready for deployment, signaling a significant shift in the pharmaceutical marketing landscape.
